Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Oct;37(5):1229-1233.
doi: 10.1007/s10792-016-0370-9. Epub 2016 Oct 11.

Alemtuzumab-induced remission of multiple sclerosis-associated uveitis

Mark D Willis  1   2 , Trevor P Pickersgill  2 , Neil P Robertson  1   2 , Richard W J Lee  3   4   5 , Andrew D Dick  3   4   5 , Ester Carreño  6
Affiliations
Case Reports

Alemtuzumab-induced remission of multiple sclerosis-associated uveitis

Mark D Willis et al. Int Ophthalmol. 2017 Oct.

Abstract

Purpose: The purpose of the study was to report a case of multiple sclerosis (MS)-associated uveitis refractory to conventional immunosuppressants, with subsequent remission following treatment with alemtuzumab.

Methods: Case report Patient was treated with intravenous alemtuzumab, a lymphocyte depleting anti-CD52 monoclonal antibody that has recently been approved for use in relapsing MS.

Results: A 17-year-old female presented with bilateral optic neuritis and subsequently bilateral intermediate uveitis and secondary macular oedema. She was diagnosed with active relapsing MS for which she received treatment with alemtuzumab. The intraocular inflammation previously refractory to conventional immunosuppressants responded to alemtuzumab, inducing remission.

Conclusions: To our knowledge, this is the first such report of alemtuzumab treatment in MS-associated ocular inflammatory disease and may demonstrate a potential utility for this drug in related conditions.

Keywords: Alemtuzumab; Intraocular inflammation; Multiple sclerosis; Uveitis.

PubMed Disclaimer

References

    1. N Engl J Med. 2008 Oct 23;359(17):1786-801 - PubMed
    1. Cytotherapy. 2001;3(3):137-43 - PubMed
    1. Neurology. 2014 Jun 17;82(24):2158-64 - PubMed
    1. Expert Rev Neurother. 2010 Dec;10(12):1789-97 - PubMed
    1. Br J Ophthalmol. 1995 Nov;79(11):1054-5 - PubMed

Publication types

Substances